n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride and Atherosclerotic Parkinsonism
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride has been researched along with Atherosclerotic Parkinsonism in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, L; Hong, J; Sha, S; Wang, C; Yin, J; Zhou, L | 1 |
Other Studies
1 other study(ies) available for n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anisoles; Astrocytes; Cell Death; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Gene Expression Regulation; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Morpholines; Neuroprotective Agents; Parkinson Disease, Secondary; Pars Compacta; Phenols; Phosphorylation; Piperidines; Propylamines; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Sigma-1 Receptor; Signal Transduction; Vesicular Monoamine Transport Proteins | 2015 |